• IM/Gastroenterology

• Fatty Liver Disease
• Hepatology

The research of Mazen Noureddin, MD, focuses on the underlying mechanisms of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), new imaging modalities and exploring new treatments. He has conducted several original studies that have been featured in publications such as Gastroenterology, Hepatology and The American Journal of Gastroenterology, among many others. The Fatty Liver Program at Cedars-Sinai has many breakthrough clinical trials targeting new therapies in patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitisn (NASH), including those with advanced fibrosis and cirrhosis.

• Residency: University of Southern California, 2005
• Fellowship: National Institutes of Health, 2008
• Master's: Duke University School of Medicine, 2009
• Fellowship: University of California, San Diego School of Medicine, 2011

• Digestive Diseases Center
• Fatty Liver Program
• Liver Disease and Transplant Center
• Department of Medicine
• Comprehensive Transplant Center

• American Liver Foundation (ALF): Health Care Visionary Award, 2016
• Clinical Scholar Program, Cedars Sinai, 2015
• Top Doctors, Pasadena Magazine, 2014, 2015
• AGA-AASLD Academic Skill Workshop. San Diego CA (invited), 2013
• 2nd Award of Research Poster Competition in San Diego Gastroenterology Society, 2012

Click here for a list of peer-reviewed publications.

• Noureddin M, Khoyliar C, Palmer SL. MRI, CT scan and ultrasound in the diagnosis of nonalcoholic fatty liver disease. J Clin Gastroenterol. 2015;49(4):351-352.
• Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood). 2015;240(6):809-820.
• Noureddin M, Rinella ME. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis. 2015;19(2):361-379.